Latest News

Axalbion therapeutics Limited, Axalbion SA's parent company, has been incorporated in UK, 24 February 2021.

Dr. Kitt joined Axalbion as Chief Executive Officer in November 2019, bringing more than 30 years of clinical development experience and industry expertise.

Results of the AX8-001 study (EudraCT no. 2017-003108-27) titled "A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH" are available on EU Clinical Trials Register:

If you need further information please feel free to contact us.